tiprankstipranks
Trending News
More News >
Danaher Corporation (DHR)
:DHR
Advertisement

Danaher (DHR) AI Stock Analysis

Compare
2,985 Followers

Top Page

DHR

Danaher

(NYSE:DHR)

Rating:66Neutral
Price Target:
$218.00
▲(9.53% Upside)
Danaher's strong financial performance and positive earnings call guidance are key strengths, supported by robust profitability and strategic innovation. However, high valuation metrics and technical indicators suggest caution. Challenges in revenue growth and market conditions, particularly in China, could impact future performance.
Positive Factors
Earnings
DHR has raised the EPS guide on the back of more favorable FX and benefit from cost actions.
Market Position
Management is comfortable with projected organizational growth and earnings per share targets for the future.
Recurring Revenue
DHR is seen as the leader in the highly attractive, recurring revenue market of bioprocess tools.
Negative Factors
Demand
Weaker demand and uncertain end-market conditions in biotech and academia offset the encouraging strength in bioprocessing.
Market Conditions
There are still headwinds, including weak US markets and a downturn in China.

Danaher (DHR) vs. SPDR S&P 500 ETF (SPY)

Danaher Business Overview & Revenue Model

Company DescriptionDanaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
How the Company Makes MoneyDanaher Corporation generates revenue through the sale of its diverse range of products and services across its three main operating segments. In the Life Sciences segment, revenue is derived from the sale of advanced scientific instruments and consumables used in research and development. The Diagnostics segment contributes through the provision of diagnostic instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment earns revenue from water quality analysis and treatment products, as well as product identification equipment and consumables. Danaher's growth and earnings are also supported by strategic acquisitions and partnerships, allowing for expansion into new markets and the enhancement of its product offerings. The company leverages its Danaher Business System, a set of tools and processes focused on continuous improvement and growth, to drive efficiency and innovation, further enhancing its profitability.

Danaher Key Performance Indicators (KPIs)

Any
Any
Recurring Revenue
Recurring Revenue
Measures the portion of revenue expected to continue in the future, indicating business stability and potential for sustained growth.
Chart InsightsDanaher's recurring revenue shows a recovery trend in 2024 after a dip in 2023, aligning with the company's strategic focus on innovation and robust consumables demand in bioprocessing. Despite challenges in the Life Sciences segment and geopolitical tensions in China, the company expects core revenue growth of 3% for the full year. The earnings call highlights strong cash flow and successful product launches, suggesting resilience and potential for long-term shareholder value despite current headwinds.
Data provided by:Main Street Data

Danaher Earnings Call Summary

Earnings Call Date:Jul 22, 2025
(Q2-2025)
|
% Change Since: 5.83%|
Next Earnings Date:Oct 28, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of strong performance in the bioprocessing and diagnostics segments, alongside challenges in life sciences and high-growth markets. The company's innovation and new product launches highlight a focus on long-term growth, while global trade tensions and market declines in China pose ongoing challenges.
Q2-2025 Updates
Positive Updates
Strong Bioprocessing Performance
Bioprocessing business showed strong growth with low double-digit growth in consumables and high single-digit growth in the biotechnology segment.
Free Cash Flow and Earnings Growth
Generated $1.1 billion of free cash flow in the quarter, with adjusted diluted net earnings per share up approximately 5% year-over-year.
New Product Launches and Innovations
Significant investments in new products like Syteva's protein A resins and XenoTOS 8600 mass spectrometry, enhancing long-term competitive positioning.
Resilience in Diagnostics
Diagnostics segment showed core revenue increase of 2%, with Cepheid's non-respiratory revenue growing double digits.
CFO Succession Plan
Announced CFO succession with Matt Gugino taking over, ensuring continuity and leadership strength.
Negative Updates
Flat Core Revenue in High-Growth Markets
Core revenues in high-growth markets were flat overall, with a mid-single-digit decline in China impacting overall performance.
Life Sciences Segment Decline
Core revenue in the life sciences segment decreased by 2.5% due to weak demand from academic and government customers.
Challenges in China
Core revenues in diagnostics in China declined due to volume-based procurement and reimbursement changes.
Global Trade Tensions Impacting Equipment Orders
Trade uncertainty and tariffs contributed to delays in large capital investment decisions, affecting equipment orders.
Company Guidance
During Danaher Corporation's second quarter 2025 earnings call, the company provided several key metrics and guidance for the year. Danaher reported sales of $5.9 billion for the second quarter, with a core revenue growth of 1.5%. The gross profit margin stood at 59.3%, while the adjusted operating profit margin was 27.3%, flat year-over-year. Adjusted diluted net earnings per share increased by approximately 5% to $1.80. The company also generated $1.1 billion in free cash flow for the quarter, resulting in a year-to-date free cash flow to net income conversion ratio of 143%. Looking ahead, Danaher maintained its full-year core revenue growth guidance at approximately 3% and increased its full-year adjusted diluted net EPS guidance to a range of $7.70 to $7.80. For the third quarter, Danaher anticipates core revenue growth in the low single-digit percent range and an adjusted operating profit margin of approximately 25.5%. The company noted robust growth in its bioprocessing business, with a high single-digit growth outlook for the second half of 2025, and highlighted strong secular growth drivers and a resilient portfolio as key factors supporting these expectations.

Danaher Financial Statement Overview

Summary
Danaher exhibits strong profitability with robust margins and a solid capital structure. However, stagnant revenue growth and challenges in sustaining free cash flow levels temper the financial outlook.
Income Statement
75
Positive
Danaher's income statement shows a consistent revenue base with a slight increase in TTM compared to the previous annual period. The gross profit margin is robust at 59.66%, and the net profit margin stands at 14.21% for the TTM, indicating healthy profitability. However, the revenue growth has been stagnant, with only a minor increase from the previous year. The EBIT and EBITDA margins remain strong at 18.39% and 25.73%, respectively, for the TTM, showcasing operational efficiency.
Balance Sheet
70
Positive
The balance sheet reveals a solid equity base with a debt-to-equity ratio of 0.33, reflecting moderate leverage levels. The equity ratio is healthy at 64.11%, suggesting a strong capital structure. Return on equity for the TTM is commendable at 6.52%, although it has decreased from previous levels, indicating a need for improved net income performance relative to equity growth.
Cash Flow
68
Positive
The cash flow statement shows a slight decrease in free cash flow from the previous year, with a negative growth rate of -8.20%. The operating cash flow to net income ratio is strong at 1.81, indicating efficient cash generation from operations. However, the free cash flow to net income ratio has decreased to 1.42, suggesting reduced cash flow available after capital expenditures.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue24.01B23.88B23.89B26.64B29.45B22.28B
Gross Profit14.77B14.21B14.03B16.19B17.95B12.47B
EBITDA6.75B7.28B7.50B9.48B10.01B6.54B
Net Income3.41B3.90B4.76B7.21B6.43B3.65B
Balance Sheet
Total Assets81.62B77.54B84.49B84.35B83.18B76.16B
Cash, Cash Equivalents and Short-Term Investments2.96B2.08B5.86B6.00B2.59B6.04B
Total Debt18.55B17.15B19.54B20.62B23.27B22.18B
Total Liabilities29.28B27.99B31.00B34.26B38.01B36.38B
Stockholders Equity52.33B49.54B53.49B50.08B45.17B39.77B
Cash Flow
Free Cash Flow4.86B5.30B5.78B7.37B7.06B5.42B
Operating Cash Flow6.17B6.69B7.16B8.52B8.36B6.21B
Investing Cash Flow-1.80B-1.98B-7.08B-2.23B-12.99B-21.24B
Financing Cash Flow-4.04B-8.38B-273.00M-2.57B1.29B1.01B

Danaher Technical Analysis

Technical Analysis Sentiment
Positive
Last Price199.04
Price Trends
50DMA
197.34
Positive
100DMA
197.01
Positive
200DMA
213.69
Negative
Market Momentum
MACD
0.50
Positive
RSI
50.57
Neutral
STOCH
43.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DHR, the sentiment is Positive. The current price of 199.04 is above the 20-day moving average (MA) of 198.44, above the 50-day MA of 197.34, and below the 200-day MA of 213.69, indicating a neutral trend. The MACD of 0.50 indicates Positive momentum. The RSI at 50.57 is Neutral, neither overbought nor oversold. The STOCH value of 43.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DHR.

Danaher Risk Analysis

Danaher disclosed 43 risk factors in its most recent earnings report. Danaher reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Danaher Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$32.64B28.3418.88%0.85%0.56%-4.08%
77
Outperform
$51.36B53.4364.87%5.56%4.66%
77
Outperform
$176.13B27.0013.44%0.35%2.05%7.03%
71
Outperform
$16.74B25.3537.03%2.57%8.31%
66
Neutral
$142.52B42.286.68%0.59%-3.24%-16.60%
63
Neutral
$25.62B30.95-680.23%3.11%8.50%
50
Neutral
AU$2.60B3.65-58.14%2.69%36.37%13.78%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DHR
Danaher
199.04
-68.19
-25.52%
A
Agilent
114.89
-20.83
-15.35%
IDXX
Idexx Laboratories
641.94
158.03
32.66%
MTD
Mettler-Toledo
1,243.94
-151.39
-10.85%
TMO
Thermo Fisher
466.42
-131.67
-22.02%
WAT
Waters
281.19
-52.15
-15.64%

Danaher Corporate Events

Executive/Board Changes
Danaher Announces General Counsel’s Upcoming Departure
Neutral
Jul 31, 2025

On July 28, 2025, Danaher Corporation announced that Brian W. Ellis, the Senior Vice President and General Counsel, will step down from his role as General Counsel on August 25, 2025. He will remain as Senior Vice President until his retirement on February 28, 2026, marking a significant transition in the company’s executive leadership.

The most recent analyst rating on (DHR) stock is a Buy with a $268.00 price target. To see the full list of analyst forecasts on Danaher stock, see the DHR Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Danaher Announces CFO Transition with Gugino Appointment
Positive
Jul 24, 2025

On July 21, 2025, Danaher Corporation announced that Matthew M. McGrew, the current Chief Financial Officer, will step down from his role on February 28, 2026, and will be succeeded by Matthew E. Gugino. Gugino, who has been with Danaher since 2013, currently serves as Vice President-Corporate FP&A and Group CFO for the Life Sciences Innovations businesses. The transition is part of a strategic move to ensure continuity in leadership as McGrew transitions towards retirement. The announcement also detailed changes in compensation for both executives, with Gugino receiving significant increases in salary and equity awards as he assumes the CFO role. This transition is expected to support Danaher’s continued growth and strengthen its position as a leader in science and technology.

The most recent analyst rating on (DHR) stock is a Buy with a $315.00 price target. To see the full list of analyst forecasts on Danaher stock, see the DHR Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Danaher Approves Key Proposals at Shareholder Meeting
Positive
May 8, 2025

On May 6, 2025, Danaher Corporation held its annual shareholder meeting where key proposals were voted on, including the election of thirteen directors and the ratification of Ernst & Young LLP as the independent accounting firm for 2025. The meeting also saw the approval of the executive compensation package, reflecting shareholder support for the company’s leadership and strategic direction.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 06, 2025